anda ppt
Drug development and regulation
Presented by: Nagori Stavan Arunkumar Department of Pharmaceutics L.M.College of Pharamcy SEMINAR ON:
Statistical Methods for Assessment of Individual/Population Bioequivalence Shein-Chung Chow, Ph.D. Biostatistics and Clinical Data Management Millennium.
Getting Your Startup to Work for You How Innovators Can Use US Patent Law to Protect Their Startups Shelly Rosenfeld Lewis Brisbois Bisgaard & Smith LLP.
FDA Generic Presentation
Brand Alternatives (Dr Brown-Myrie)
IPR NDA and ANDA
FDA Counsel.com 1 ANDAs, OTCs, Orphans and Cosmetics -- Key Issues Wednesday, August 18, 2004 SDRAN RAC STUDY COURSE Michael A. Swit, Esq. FDACounsel.com.
The Hatch-Waxman Act and How it Works: Balancing Incentives to Innovate with the Need for Affordable Drugs Minnesota Intellectual Property Association.
Potential Impact on Data Exclusivity: A Necessary Form of IP in a FOB World Susan Finston, President “Biosimilars and Follow-On Biologics” Doubletree Hotel,
Development & The US FDA Approval of Generic Drugs May 18, 2011 | Beijing, China SHAO Jun, Ph.D.
